Koo,

Thanks for posting about the Pfizer Fyzoclad news. I wasn't aware of that. I did post on the prior FDA/EMA Canakinumab withdrawal in this thread. The CANTOS trial results were promising and good validation of the inflammation hypothesis. But CANTOS results weren't be totally clean cut and Novartis may have been overreaching a bit with their trial claims and FDA/EMA weren't in board.

BearDownAZ